BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 21883849)

  • 21. Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy.
    Abdi H; Pourmalek F; Gleave ME; So AI; Black PC
    World J Urol; 2016 Jan; 34(1):41-8. PubMed ID: 26621208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
    Tilki D; Reich O; Svatek RS; Karakiewicz PI; Kassouf W; Novara G; Ficarra V; Chade DC; Fritsche HM; Gerwens N; Izawa JI; Lerner SP; Schoenberg M; Stief CG; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
    J Urol; 2010 May; 183(5):1757-63. PubMed ID: 20299059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Dhar NB; Jones JS; Reuther AM; Dreicer R; Campbell SC; Sanii K; Klein EA
    BJU Int; 2008 Apr; 101(8):969-72. PubMed ID: 18005201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and density.
    Wiesner C; Salzer A; Thomas C; Gellermann-Schultes C; Gillitzer R; Hampel C; Thüroff JW
    BJU Int; 2009 Aug; 104(3):331-5. PubMed ID: 19220265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality.
    Lughezzani G; Sun M; Jeldres C; Alasker A; Budäus L; Shariat SF; Latour M; Widmer H; Duclos A; Jolivet-Tremblay M; Montorsi F; Perrotte P; Karakiewicz PI
    Urology; 2010 Feb; 75(2):376-81. PubMed ID: 20022091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
    Lotan Y; Gupta A; Shariat SF; Palapattu GS; Vazina A; Karakiewicz PI; Bastian PJ; Rogers CG; Amiel G; Perotte P; Schoenberg MP; Lerner SP; Sagalowsky AI
    J Clin Oncol; 2005 Sep; 23(27):6533-9. PubMed ID: 16116151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy.
    Baumann BC; Guzzo TJ; He J; Vaughn DJ; Keefe SM; Vapiwala N; Deville C; Bekelman JE; Tucker K; Hwang WT; Malkowicz SB; Christodouleas JP
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):363-9. PubMed ID: 22658217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
    Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
    J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymph node yield in node-negative patients predicts cancer specific survival following radical cystectomy for transitional cell carcinoma.
    Crozier J; Papa N; Perera M; Stewart M; Goad J; Sengupta S; Bolton D; Lawrentschuk N
    Investig Clin Urol; 2017 Nov; 58(6):416-422. PubMed ID: 29124240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stage specific lymph node metastasis mapping in radical cystectomy specimens.
    Vazina A; Dugi D; Shariat SF; Evans J; Link R; Lerner SP
    J Urol; 2004 May; 171(5):1830-4. PubMed ID: 15076287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
    Hautmann RE; de Petriconi RC; Pfeiffer C; Volkmer BG
    Eur Urol; 2012 May; 61(5):1039-47. PubMed ID: 22381169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection.
    Dhar NB; Campbell SC; Zippe CD; Derweesh IH; Reuther AM; Fergany A; Klein EA
    BJU Int; 2006 Dec; 98(6):1172-5. PubMed ID: 16956353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic value of lymph node dissections in bladder cancer treated with radical cystectomy].
    Braud G; Battisti S; Karam G; Bouchot O; Rigaud J
    Prog Urol; 2008 Jun; 18(6):351-7. PubMed ID: 18558323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients.
    Morgan TM; Barocas DA; Penson DF; Chang SS; Ni S; Clark PE; Smith JA; Cookson MS
    Urology; 2012 Sep; 80(3):632-40. PubMed ID: 22795379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival.
    Bastian PJ; Hutterer GC; Shariat SF; Rogers CG; Palapattu GS; Lotan Y; Vazina A; Amiel GE; Gupta A; Sagalowsky AI; Lerner SP; Schoenberg MP; Karakiewicz PI;
    BJU Int; 2008 Feb; 101(4):450-4. PubMed ID: 17850359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer.
    Fang AC; Ahmad AE; Whitson JM; Ferrell LD; Carroll PR; Konety BR
    Cancer; 2010 Apr; 116(8):1901-8. PubMed ID: 20186823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.
    Rink M; Ehdaie B; Cha EK; Green DA; Karakiewicz PI; Babjuk M; Margulis V; Raman JD; Svatek RS; Fajkovic H; Lee RK; Novara G; Hansen J; Daneshmand S; Lotan Y; Kassouf W; Fritsche HM; Pycha A; Fisch M; Scherr DS; Shariat SF; ;
    Eur Urol; 2012 Oct; 62(4):677-84. PubMed ID: 22349570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of lymph node dissection on stage-specific survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy.
    Zhai TS; Jin L; Zhou Z; Liu X; Liu H; Chen W; Lu JY; Yao XD; Feng LM; Ye L
    BMC Cancer; 2019 Dec; 19(1):1207. PubMed ID: 31830927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.